Investigators - Basic - nelson

Peter Nelson, MD

Project 1: The Nephrotic Syndrome Study Network (NEPTUNE)

NEPTUNE is a multi-center observational study of subjects with incipient minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy. The major goals of this study are to identify new clinical and molecular biomarkers that predict progression versus non-progression of disease and response versus no response to treatment, and to identify new drug targets for these diseases.

Trial Location: University of Washington Medical Center (UWMC)
Recruitment: OPEN
Contact Info: Laura Curtin; phone: 206-221-3938 or email: lcurtin@nephrology.washington.edu

Project 2: Membranous Nephropathy Trial of Rituximab (MENTOR)

MENTOR is a multi-center interventional study of subjects with idiopathic membranous nephropathy. The major goal of this study is to determine whether Rituximab is better than Cyclosporine for treating subjects with membranous nephropathy.

Trial Location: University of Washington Medical Center
Recruitment: OPEN
Contact Info: Laura Curtin; phone: 206-221-3938 or email: lcurtin@nephrology.washington.edu

Project 3: RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis (DUET)

DUET is a multi-center interventional study of subjects with focal segmental glomerulosclerosis. The major goal of this study is to determine whether Sparsentan is safe and effective in treating patients with focal segmental glomerulosclerosis.

Trial Location: University of Washington Medical Center
Recruitment: PENDING

Project 4: Cure Glomerulonephropathy Network (CureGN)

CureGN is a multi-center observational study of subjects with IgA nephropathy, minimal change disease, focal segmental glomerulosclerosis, or membranous nephropathy. The major goals of this study are to determine the causes for these diseases and their progression and response to treatment.

Trial Location: University of Washington Medical Center
Recruitment: PENDING

Project 5: Fresolimumab in Focal Segmental Glomerulosclerosis

The Fresolimumab in FSGS study is a multi-center interventional study of subjects with focal segmental glomerulosclerosis. The major goal of this study is to determine whether Fresolimumab is safe and effective in treating patients with focal segmental glomerulosclerosis.

Trial Location: University of Washington Medical Center
Recruitment: CLOSED

Current Funding

R01 DK083375 (Nelson, PI)
NIH/NIDDK
Immunocytoprotection in collapsing glomerulopathy

U54 DK083912 (Clinical Center: Nelson, PI)
NIH/NIDDK and NIH/ORD
The Nephrotic Syndrome Study Network (NEPTUNE)

Sponsored Research Grant (Nelson, PI)
Genzyme Corporation
Pre-clincal testing of Genz-123 in a murine model of collapsing glomerulopathy

Past Funding

R01 DK083375-S1 (Nelson, PI) NIH/NIDDK
Re-entry supplement to DK083375

R03 DK079498 (Nelson, PI)
NIH/NIDDK
TNF-α: an immunologic precipitant of collapsing glomerulopathy

K08 DK065498 (Nelson, PI)
NIH/NIDDK
Immune mechanisms in collapsing glomerulopathy

Saperstein Grant (Nelson, PI)
Michael Saperstein Scholarship Program
Dendritic cells in proteinuria

Sponsored Research Grant (Nelson, PI)
Cyclacel, Ltd
Pre-clinical optimization of CYC202 in a murine model of collapsing glomerulopathy

Sponsored Research Grant (Nelson, PI)
Cyclacel, Ltd
Pre-clinical testing of CYC202 in a murine model of collapsing glomerulopathy

Research Fellowship Grant (Nelson, PI)
National Kidney Foundation
Targeting cell-cycle progression in HIV-associated collapsing glomerulopathy

Publications

PubMed provides a list of Dr. Nelson's research publications

[top]